Despite posting record orders, raising its annual guidance, and actively buying back its own shares, Siemens AG’s stock has been under pressure. This divergence between robust operational performance and a declining share price presents a curious paradox for investors examining the industrial conglomerate.
Financial Performance and Guidance Upgrade
The company’s first quarter for fiscal 2026 demonstrated significant strength across key metrics. Revenue climbed 8% to €19.1 billion, while new orders surged 10% to reach €21.4 billion. This performance resulted in a book-to-bill ratio of 1.12, indicating that order intake continues to outpace revenue recognition. Siemens’ order backlog hit a new record of €120 billion. On a per-share basis, adjusted earnings jumped to €2.80, a substantial increase from €2.22 in the prior-year period.
In response to this strong start, management upgraded its full-year outlook. The company now anticipates adjusted earnings per share will land between €10.70 and €11.10. Revenue growth is projected to reach the upper half of the previously guided range of 6% to 8%.
Strategic Growth Engines: Data Centers and AI
A primary driver of this growth is the dynamic data center business, where revenue expanded by 35%. Siemens is capitalizing on sustained global demand for cloud infrastructure, with particularly strong momentum in the United States.
Concurrently, the company is making significant investments to position artificial intelligence (AI) as the cornerstone of future manufacturing. A €200 million investment is underway to transform its Amberg plant into a fully AI-controlled factory by 2030. Furthermore, in collaboration with NVIDIA, Siemens plans to launch initial reference projects for autonomous, self-learning production systems in Erlangen starting this year.
Structural Uncertainty Weighs on Shares
Market analysts suggest the stock’s weakness is less about fundamentals and more related to impending structural changes within the corporation. The board of directors has approved a plan to distribute approximately 30% of Siemens Healthineers shares directly to Siemens shareholders. This move would see Siemens relinquish its controlling majority in the medical technology subsidiary, eventually holding Healthineers only as a financial investment.
The lack of detail is a key concern. CEO Roland Busch is expected to provide specifics on the timeline and tax implications in the second calendar quarter of 2026. Until then, the market lacks clarity, contributing to investor caution. The share price currently trades around €221, notably below its 200-day moving average of €235. Since the start of the year, the stock has declined nearly 8%.
An upcoming change in financial leadership adds another layer of transition. On April 1, Veronika Bienert will assume the role of CFO from Ralf P. Thomas, who is stepping down after more than a decade in the position.
Share Buyback and the Path Forward
Amid these developments, Siemens continues to execute its substantial share repurchase program at a brisk pace. Of the authorized €6 billion, approximately €4.4 billion has already been utilized. The company is scheduled to retire 18 million of its own shares in March, a move that provides direct support to earnings per share.
The critical test for the equity will likely be the forthcoming clarification on the Healthineers transaction this quarter. Only once the schedule and tax structure are finalized can investors properly assess whether the spin-off represents a burden or a value-creating strategic step. The market will be watching for the next quarterly results, scheduled for release on May 13, 2026.
